Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Rating of “Hold” by Brokerages

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) have been given an average rating of “Hold” by the six analysts that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $5.00.

ZNTL has been the topic of a number of recent research reports. Wall Street Zen upgraded shares of Zentalis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, November 16th. Morgan Stanley lowered their price target on shares of Zentalis Pharmaceuticals from $8.00 to $4.00 and set an “equal weight” rating for the company in a report on Wednesday, November 12th. Leerink Partners restated a “market perform” rating and issued a $2.00 price objective on shares of Zentalis Pharmaceuticals in a report on Tuesday, November 11th. Finally, Wedbush reiterated a “neutral” rating and set a $4.00 target price on shares of Zentalis Pharmaceuticals in a research note on Tuesday, November 11th.

Zentalis Pharmaceuticals Price Performance

Shares of NASDAQ:ZNTL opened at $2.42 on Friday. The firm has a market capitalization of $174.85 million, a PE ratio of -1.17 and a beta of 1.73. Zentalis Pharmaceuticals has a 1 year low of $1.01 and a 1 year high of $3.95. The firm’s 50-day moving average is $2.28 and its two-hundred day moving average is $1.79.

Insider Activity at Zentalis Pharmaceuticals

In other Zentalis Pharmaceuticals news, insider Vincent Vultaggio sold 29,951 shares of the stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $2.43, for a total value of $72,780.93. Following the transaction, the insider directly owned 156,779 shares in the company, valued at $380,972.97. This represents a 16.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Group Walters acquired 6,459,973 shares of the business’s stock in a transaction on Wednesday, December 31st. The shares were bought at an average cost of $1.20 per share, for a total transaction of $7,751,967.60. Following the acquisition, the insider owned 13,509,973 shares of the company’s stock, valued at $16,211,967.60. This represents a 91.63% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders sold 7,546,617 shares of company stock valued at $10,088,417 over the last three months. 1.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Sivia Capital Partners LLC purchased a new position in shares of Zentalis Pharmaceuticals during the fourth quarter worth about $27,000. Catalyst Funds Management Pty Ltd purchased a new position in Zentalis Pharmaceuticals during the 2nd quarter worth approximately $31,000. Qube Research & Technologies Ltd purchased a new position in Zentalis Pharmaceuticals during the 2nd quarter worth approximately $37,000. Y Intercept Hong Kong Ltd acquired a new position in Zentalis Pharmaceuticals during the second quarter worth approximately $38,000. Finally, Corient Private Wealth LLC purchased a new stake in Zentalis Pharmaceuticals in the second quarter valued at approximately $41,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.